Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
A proline-rich pentadecapeptide. The sequence is stable enough that the preclinical literature describes gastric-juice stability. That property is not an oral dosing instruction.
It is not a dopamine-receptor antagonist, and it is not a stimulant. Forum language that treats the rat stereotypy papers as loss of a prescribed stimulant effect is a misreading of the chemistry.
The peptide is a fragment of a gastric protective protein. Preclinical work connects it to nitric oxide signaling, angiogenic markers such as VEGF, and extracellular-matrix turnover.
The dopamine link in this sheet comes from rodent behavior with amphetamine, not from a solved crystal structure of BPC-157 on a dopamine receptor.
Forums turn that behavior paper into a stimulant story. The pathway on file is modulation in animals, with intraperitoneal exposure in the 1998 study and an unextracted route in the 2002 study.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Repair stack · unverified
Public peptide forums routinely pair BPC-157 with TB-500, and sometimes with GHK-Cu or KPV, under blend names such as Glow or KLOW. The posts are anecdotes about tissue comfort and injection sites. They are not co-exposure trials.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.